Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1519-1521

  Fjalling M ^a   Andersson, P ^a   Forssell Aronsson, E ^a   Gretarsdottir J ^a   Johansson, V ^a   Tisell, L E ^a   Wangberg B ^a   Nilsson, O ^a   Berg, G ^a   Michanek, A ^a   Lindstedt, G ^a   Ahlman, H ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Indium 111 DTPA D Phe1 octreotide; midgut carcinoid; systemic radionuclide therapy

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; PENTETREOTIDE IN 111;

ADULT; ARTICLE; BONE METASTASIS; CARCINOID SYNDROME; CASE REPORT; DRUG EFFECT; FEMALE; HUMAN; ILEUM CANCER; LIVER METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; METASTASIS; MIDGUT; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY;

FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; INDIUM RADIOISOTOPES; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; OCTREOTIDE; PENTETIC ACID; RADIOTHERAPY DOSAGE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 10144219957     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Reubi JC, Maurer R, von Werder K, Torholst J, Klijn J, Lamberts SWJ. Somatostatin receptors in human endocrine tumors. Cancer Res 1987;47:551-558.
2. Reubi JC, Krenning E, Lamberts SWJ, Kvols L. Somatostatin receptors in malignant tissue. J Steroid Biochem Mol Biol 1990;37:1073-1077.
3. Gorden P, Comi RJ, Maton PN, Go VLW. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110:35-52.
4. 1-octreotide for detection of somatostatin receptor-positive tumours in rats. Life Sci 1991;49:1593-1601.
5. Lamberts SWJ, Bakker W, Reubi JC, Krenning E. Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med 1990;323:1246-1253.
6. Ahlman H, Wängberg B, Tisell LE, Nilsson O, Fjälling M, Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 1994;81:1144-1149.
7. Raulf F, Pérez J, Hoyer D, Bruns C. Differential expression of five somatostatin receptor subtypes. SSTR 1-5, in the CNS and peripheral tissue. Digestion 1994;55: 46-53.
8. 1-octreotide. J Nucl Med 1995;36:7-12.
9. 1]-octreotide. Ann NY Acad Sci 1994;773: 496-506.
10. Ajani JA, Carrasco CH, Wallace S. Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy. Ann NY Acad Sci 1994;773:479-487.
11. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations, revised. New York: The Society of Nuclear Medicine; 1991.
12. Davis Z, Moertel C, Mc Ilrath D. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973;137:637-641.